COMPANY PROFILE

CGI Pharmaceuticals

Explore full profile

Private, development-stage pharmaceutical company

Branford, United StatesFounded 1998Biotech & Life Sciences

Valuation $100–250M Last recorded · 2010

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About CGI Pharmaceuticals

CGI Pharmaceuticals, founded in 2000 out of Yale University, specialized in kinase drug discovery. The company was acquired by Gilead Sciences in July 2010. CGI's research laboratories, located in Branford, Connecticut, continue to operate under Gilead, focusing on the development of kinase inhibitors. The business primarily serves the pharmaceutical and biotechnology sectors, targeting diseases where kinase inhibitors can be effective. CGI Pharmaceuticals operated on a venture-backed business model before its acquisition, generating revenue through the development and licensing of its drug discovery technologies. The acquisition by Gilead allowed for continued research and development under a larger corporate umbrella, ensuring sustained innovation and contribution to the field of kinase drug discovery.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 1998
Headquarters: Branford, United States
Employees: 10
Open positions: None listed
Dealroom signal: 54.1/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Jun 2010	$120M	$120M	Undisclosed	—
SERIES C✓Equity / VC	Jan 2004	$22M	$89M	Flagship Pioneering · MPM BioImpact · ETP Ventures · Connecticut Innovations	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

CGI Pharmaceuticals website traffic

Latest recorded traffic for CGI Pharmaceuticals is 0 monthly website visits, down 100% over the last three months. CGI Pharmaceuticals's team declined 33.3% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth-33.3%

Monthly website visitsJan 2020–Oct 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
INInVirtuoLabsModular AI solutions accelerating drug discovery with predictive models and generative simulations	Lugano, Switzerland	Operational	16	$3.1M	$13M
PAPanacea-mlExplainable-AI Platform to Streamline Clinical Trial Design	Ra'anana, Israel	Operational
EPEpiternaDeveloping affordable products that can safely slow the ageing process to prevent age-related disease, delay functional decline, and extend life	Epalinges, Switzerland	Operational
DPDISCO PharmaceuticalsBiotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds	Cologne, Germany	Operational
VIVilyaDeveloping a novel class of drugs that precisely target the biology of disease	Seattle, United States	Operational
CHChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa	Glasgow, United Kingdom	Operational
PRPromptlyA global provider of end-to-end Real-World Evidence solutions, generating new knowledge from harmonized datasets to improve healthcare outcomes at lower costs	Porto, Portugal	Operational
MTMETiS TherapeuticsAI-driven platform for drug discovery and delivery	Cambridge, United States	Operational